RXI Pharma (RXII) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Nasdaq climbs to record after softer jobs data cools rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- Wells Fargo names 13 stocks as overweight tactical ideas
RXi Pharmaceuticals Reports Third Quarter 2016 Financial Results and Highlights Recent Corporate Developments
November 10, 2016 7:02 AM ESTMARLBOROUGH, Mass., Nov. 10, 2016 /PRNewswire/ --Â RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today reported its financial results for the third quarter ended September 30, 2016, and provided a business update.
Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
"In the third quarter of 2016, RXi has once again been able to keep its cash burn in line with our projections, while continuing the clinical... More
